Rebound tonometer comparable to Goldmann applanation

Article

IOP measurements obtained with the rebound tonometer (Icare Pro) are more comparable to those achieved with the Goldmann applanation tonometer than those obtained with ultra-high-speed Scheimpflug technology, according to a recent study.

IOP measurements obtained with the rebound tonometer (Icare Pro) are more comparable to those achieved with the Goldmann applanation tonometer than those obtained with ultra-high-speed Scheimpflug technology, according to a study published in Investigative Ophthalmology & Visual Science (IOVS).

For this comparison study, researchers from the Medical University of Silesia, in Katowice, Poland, included 192 eyes of 96 patients, 152 of which were healthy and measured IOPs using the Goldmann applanation tonometer (GAT), a rebound tonometer (RT; Icare PRO), and ultra-high-speed Scheimpflug Technology (UHS ST). Corneal pachymetry was also done with a Scheimpflug camera and an ultrasound pachymeter (A-scan Plus, Accutome) as a comparison for Corvis ST pachymetry.

Mean IOPs were 15.6 mmHg (GAT), 15.6 mmHg (RT), and 16.1 mmHg (UHS ST). Mean central corneal thickness (CCT) was 543.7 μm (UHS ST), 547.9 μm (Pentacam) and 556.25 μm (ultrasound pachymeter).

Researchers noted a significant difference between IOP measurements obtained with GAT and RT compared to measurements obtained with the UHS ST (P P = 0.5). In addition, no significant differences were seen in CCT measured via UHS ST, Pentacam and ultrasound pachymeter.

To access the abstract of this study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.